Nolte H, Gjedde S B, Lindegaard-Madsen E, Bergh J, Blomquist E, Mouridsen H T
Department of Oncology ONA, Finsen Institute/Rigshospitalet, Copenhagen, Denmark.
Eur J Cancer Clin Oncol. 1989 Apr;25(4):655-7. doi: 10.1016/0277-5379(89)90201-0.
Forty-seven patients with metastatic malignant melanoma took part in a phase II trial of tauromustine (TCNU), a new chlorethylnitrosourea based on the endogenous amino acid taurine. TCNU was given orally at a dosage of 130 mg/m2 every fifth week. No patient had previously received cytotoxic therapy. Among 37 evaluable patients, 26 patients experienced progressive disease including seven patients with early death, five showed no change, and six partial responses, yielding an objective response rate of 16%. Responses were limited to subcutaneous, lymph node, bone and lung metastases. Median time to progression was 26 weeks for responders. The treatment schedule was well tolerated with a median dose of 88% of the predicted dose given during all cycles. Dose-limiting toxicity was thrombocytopenia. It appears that TCNU is active in disseminated malignant melanoma with a response rate similar to other nitrosoureas.
47例转移性恶性黑色素瘤患者参与了一项关于牛磺莫司汀（氯乙亚硝脲）的II期试验，这是一种基于内源性氨基酸牛磺酸的新型氯乙亚硝脲。牛磺莫司汀每五周口服一次，剂量为130mg/m²。此前没有患者接受过细胞毒性治疗。在37例可评估的患者中，26例病情进展，其中7例早期死亡，5例无变化，6例部分缓解，客观缓解率为16%。缓解仅限于皮下、淋巴结、骨和肺转移。缓解者的中位疾病进展时间为26周。治疗方案耐受性良好，所有周期给予的中位剂量为预测剂量的88%。剂量限制性毒性为血小板减少症。看来牛磺莫司汀对播散性恶性黑色素瘤有活性，缓解率与其他亚硝脲类药物相似。
